A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Inclusion Criteria:

1. Sign the informed consent form voluntarily and follow the protocol requirements;

2. Gender is not limited;

3. Age: ≥18 years old and ≤75 years old;

4. Expected survival time ≥3 months;

5. Patients with histologically and/or cytologically confirmed locally advanced ormetastatic solid tumors such as non-small cell lung cancer and nasopharyngealcarcinoma;

6. Consent to provide archival tumor tissue samples or fresh tissue samples fromprimary or metastatic lesions within 2 years;

7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

8. ECOG 0 or 1;

9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as definedby NCI-CTCAE v5.0;

10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

11. No blood transfusion, no use of cell growth factors and/or platelet raising drugswithin 14 days before the first use of the study drug, and the level of organfunction must meet the requirements;

12. Coagulation function: international normalized ratio ≤1.5, and activated partialthromboplastin time≤1.5 ULN;

13. Urinary protein ≤2+ or ≤1000mg/24h;

14. For premenopausal women with childbearing potential, a pregnancy test must beperformed within 7 days before starting treatment, serum or urine must be negativefor pregnancy, and must be non-lactating; All enrolled patients (male or female)were advised to use adequate barrier contraception throughout the treatment cycleand for 6 months after the end of treatment.

Exclusion Criteria:

1. For stage 3 Cohort_A, patients with MET 14 exon skipping detected by gene sequencingreport before signing informed consent;

2. Chemotherapy, biological therapy and other anti-tumor therapies have been usedwithin 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureaswere administered within 6 weeks before the first dose; Oral drugs such asfluorouracil;

3. Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-relatedmyocarditis;

4. Use of immunomodulatory drugs within 14 days before the first dose of study drug;

5. History of severe heart disease;

6. QT prolongation, complete left bundle branch block, III degree atrioventricularblock;

7. Systemic corticosteroids or immunosuppressive agents are required within 2 weeksbefore study dosing;

8. Active autoimmune and inflammatory diseases;

9. Other malignancies diagnosed within 5 years before the first dose;

10. Hypertension poorly controlled by two antihypertensive drugs;

11. Pulmonary disease was defined as grade ≥3 according to CTCAE v5.0; Patients withcurrent or history of ILD;

12. Unstable thrombotic events requiring therapeutic intervention within 6 months beforescreening;

13. Patients with a large amount of serous cavity effusion, or serous cavity effusionwith symptoms, or within 4 weeks before signing informed consent;

14. Patients with active central nervous system metastases;

15. Patients with a history of allergy to recombinant humanized antibody or human-mousechimeric antibody or to any excipients of the test drug;

16. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;

17. Human immunodeficiency virus antibody positive, active tuberculosis, activehepatitis B virus infection or hepatitis C virus infection;

18. Active infection requiring systemic therapy;

19. Had participated in another clinical trial within 4 weeks before the first dose;

20. The investigator did not consider it appropriate to use other conditions forparticipation in the trial.